Get the Stockscreener App
18.77
28.77%
-7.4414
Summit Therapeutics Inc stock is traded at $18.77, with a volume of 17.12M.
It is down -28.77% in the last 24 hours and down -22.60% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$26.21
Open:
$21.2
24h Volume:
17.12M
Relative Volume:
4.26
Market Cap:
$13.93B
Revenue:
$956.00K
Net Income/Loss:
$-221.32M
P/E Ratio:
-58.65
EPS:
-0.32
Net Cash Flow:
$-142.25M
1W Performance:
-27.78%
1M Performance:
-22.60%
6M Performance:
+1.14%
1Y Performance:
+70.97%
1-Day Range:
$18.01
$21.63
1-Week Range:
$18.01
$27.09
52-Week Range:
$6.78
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.76 | 19.14B | 956.00K | -221.32M | -142.25M | -0.32 |
|
ONC
Beone Medicines Ltd Adr
|
245.77 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.41 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.93 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.40 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab Approval (SMMT) - Seeking Alpha
Summit's Shares Fall Despite Progression-Free Survival Gains in Ivonescimab Trial - marketscreener.com
Summit Therapeutics Stock Tumbles On Oncology Drug Trial Data, Retail Flags ‘Insane’ Valuation By Stocktwits - Investing.com India
Summit’s disappointing survival readout raises stakes for full data - Endpoints News
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down. - Barron's
Summit Says Ivonescimab Significantly Improves Progression-Free Survival; Overall Survival Trend Not Statistically Significant -- Shares Drop - marketscreener.com
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival Endpoint - Benzinga
Summit stock down after cancer trial data (update) (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics (SMMT) Advances Lung Cancer Drug with Positi - GuruFocus
Summit Therapeutics stock dips after clinical trial results - Investing.com
Summit Therapeutics stock dips after clinical trial results By Investing.com - Investing.com UK
Summit shrugs off survival miss with its VEGF bispecific - pharmaphorum
Summit Therapeutics (SMMT): Ivonescimab Plus Chemo Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients with EGFR-Mutant NSCLC - StreetInsider
Summit Therapeutics (SMMT) Reveals Promising Phase III Trial Out - GuruFocus
Summit Therapeutics (SMMT) Surges Following HARMONi Trial Result - GuruFocus
Trading (SMMT) With Integrated Risk Controls - news.stocktradersdaily.com
MRK Down 21% YTD: Should You Buy, Hold or Sell the Stock? - Zacks Investment Research
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect? - Yahoo Finance
3 High-Flying Stocks That Could Soar Even More - Yahoo Finance
Summit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025 - Yahoo Finance
Summit Therapeutics (SMMT) Receives Buy Rating and $33 Target | - GuruFocus
Summit Therapeutics (SMMT) Receives Buy Rating from Clear Street - GuruFocus
Summit Therapeutics (SMMT) Receives Buy Rating from Clear Street | SMMT Stock News - GuruFocus
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 - The Globe and Mail
Summit Therapeutics reports inducement grants - Medical Buyer
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money - Yahoo Finance
(SMMT) Trading Report - news.stocktradersdaily.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SMMT Stock News - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
BioNTech says bispecific antibody BNT327 is competitive against Summit's ivonescimab (BNTX:NASDAQ) - Seeking Alpha
Dimensional Fund Advisors LP Acquires 160,592 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Summit Therapeutics Inc. (NASDAQ:SMMT) Receives $37.40 Consensus PT from Analysts - Defense World
Hsbc Holdings PLC Invests $188,000 in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Shareholders that lost money on Summit Therapeutics Inc.(SMMT) should contact Levi & Korsinsky about Securities Fraud InvestigationSMMT - ACCESS Newswire
Summit Therapeutics (NASDAQ:SMMT) Upgraded at TD Cowen - Defense World
Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud InvestigationSMMT - ACCESS Newswire
Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline - Investing.com Canada
SMMT ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Summit Therapeutics Inc. Shareholders Who Lost Money - ACCESS Newswire
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Summit Therapeutics (SMMT) Receives Positive Coverage from TD Co - GuruFocus
Summit Therapeutics (SMMT) Receives Positive Coverage from TD Cowen | SMMT Stock News - GuruFocus
Summit Therapeutics stock rating upgraded to Buy at TD Cowen By Investing.com - Investing.com India
Summit Therapeutics stock rating upgraded to Buy at TD Cowen - Investing.com
Can Summit Therapeutics Stock Double Your Money? - Nasdaq
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know - Yahoo Finance
(SMMT) Trading Advice - news.stocktradersdaily.com
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial - MSN
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN
Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):